RELUGOLIX
Ultra-HERO
Phase 2 small_molecule active
Quick answer
RELUGOLIX for Intermediate risk prostate cancer is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- Intermediate risk prostate cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active